Bax inhibition protects against free fatty acid-induced lysosomal permeabilization
- 1 June 2006
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 290 (6) , G1339-G1346
- https://doi.org/10.1152/ajpgi.00509.2005
Abstract
Lysosomal permeabilization is a key feature of hepatocyte lipotoxicity, yet the mechanisms mediating this critical cellular event are unclear. This study examined the mechanisms involved in free fatty acid (FFA)-induced lysosomal permeabilization and the role of Bax, a Bcl-2 family member, in this event. Exposure of liver cells to palmitate induced Bax activation and translocation to lysosomes. Studies to suppress Bax activation either by pharmacological approaches or small interfering-RNA-mediated inhibition of Bax expression showed that lysosomal permeabilization is Bax dependent. In addition, palmitate treatment resulted in a significant decrease in Bcl-XL, a Bax antagonist. Moreover, forced Bcl-XL expression blocked lysosomal permeabilization. Lysosomal permeabilization by FFA was ceramide and caspase independent. Finally, paradigms that inhibit lysosomal permeabilization also reduced apoptosis. In conclusion, these data strongly support a regulatory role for Bax in FFA-mediated lysosomal permeabilization and subsequent cell death.Keywords
This publication has 40 references indexed in Scilit:
- TNF-α-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependentAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Fatty liver, hypertension, and the metabolic syndromeGut, 2004
- Lysosomes in cell deathOncogene, 2004
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70Nature Cell Biology, 2003
- The Bcl2 family: regulators of the cellular life-or-death switchNature Reviews Cancer, 2002
- Mechanisms of LipoapoptosisTrends in Cardiovascular Medicine, 2002
- Lipotoxic DiseasesAnnual Review of Medicine, 2002
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998